CTOs on the Move

NextCure

www.nextcure.com

 
NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.nextcure.com
  • 9000 Virginia Manor Road Suite 200
    Beltsville, MD USA 20705
  • Phone: 240.399.4900

Executives

Name Title Contact Details

Funding

NextCure raised $93M on 11/13/2018

Similar Companies

InGeneron

Founded in 2006, InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. The company was formed to innovate cell-based technologies for healthcare and life science research. Headquartered in Houston, Texas,

CombiMatrix Corporation

CombiMatrix Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novagen

Novagen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

William Gallagher Associates

William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Yield10 Bioscience

Yield10 Bioscience is an agricultural bioscience company focusing on the development of disruptive technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. Experts forecast that food production must be increased by over 70% in the next 35 years to feed the growing global population, which is expected to increase from 7 billion to more than 9.6 billion by 2050. Yield10 is focused on new agricultural biotechnology approaches to improve fundamental elements of plant metabolism through enhanced photosynthetic efficiency and directed carbon utilization. Yield10 is working to develop, validate and commercialize new traits and identify gene editing targets in several key crops including canola, soybean and corn. Yield10 was launched by Metabolix, Inc. in 2015 and is traded on Nasdaq (YTEN). Yield10 is headquartered in Woburn, MA and has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.